NASDAQ · ACAD
ACADIA Pharmaceuticals Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ACAD: Nov 04, 2026
ACADIA Pharmaceuticals Inc. Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $0.19. The reported EPS for the same quarter last year was $0.26.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.19 | $0.28 | $0.11 | 7 |
| Dec 2026 | $0.25 | $0.39 | $0.14 | 7 |
| Mar 2027 | $0.18 | $0.27 | $0.09 | 2 |
| Jun 2027 | $0.20 | $0.27 | $0.12 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel · BNK Invest- Zacks · Oct 29, 9:00 AM EDTRegenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 29, 3:58 AM EDTTarsus Names Neera Clase Commercial Chief To Expand XDEMVY Reach And Lead Pipeline Planning(RTTNews) – Wednesday, Tarsus Pharmaceuticals, Inc. (TARS) said it has appointed Neera Clase as Chief Commercial Officer (CCO), effective November 1, 2026.
- Zacks · Oct 28, 9:00 AM EDTEarnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to DeclineAcadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Fintel · Oct 23, 7:39 PM EDTACADIA Pharmaceuticals Inc. Announces Departure and Consulting Agreement for Dr. Elizabeth H.Z. ThompsonACADIA Pharmaceuticals Inc. announced that Elizabeth H.Z. Thompson, Ph.D., has stepped down from her role as Executive Vice President, Head of Research and Development. As of October 23, 2026, Dr. Thompson no longer serves as an employee of the company or functions in her former
- Zacks · Oct 21, 10:00 AM EDTWill Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.
- Zacks · Oct 13, 9:01 AM EDTCan Nuplazid and Daybue Strengthen Acadia's Growth Prospects?ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.
- Zacks · Oct 9, 9:28 AM EDT4 CNS Drug Stocks Worth Watching This World Mental Health DayAXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
- Zacks · Sep 29, 9:06 AM EDTAcadia's Daybue Patent Allowance Extends U.S. Protection to March 2041ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.
- BNK Invest · Sep 28, 3:36 PM EDTNoteworthy Monday Option Activity: INTC, LLY, ACADLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Intel Corp (Symbol: INTC), where a total volume of 925,123 contracts has been traded thus far today, a contract volume which is representative of approximately 9
- Zacks · Sep 25, 11:02 AM EDTACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary GoalAcadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.
- MarketBeat · Sep 24, 11:03 AM EDTACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis TrialAcadia Pharmaceuticals: A Mid-Cap Biotech Making Large MovesACADIA Pharmaceuticals (NASDAQ:ACAD) reported top-line results from the phase II portion of its RADIANT clinical program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psych
- RTTNews · Sep 24, 9:53 AM EDTAcadia's Remlifanserin Phase 2 Data Support Phase 3 Development In Alzheimer's Psychosis(RTTNews) – Acadia Pharmaceuticals (ACAD) announced topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating Remlifanserin in patients with Alzheimer's disease psychosis.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for ACADIA Pharmaceuticals Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.